Medable, a leading clinical trial technology platform, has been recognized as a Trailblazer in Everest Group’s first-ever “Clinical Trial Patient Engagement Products Assessment.” This recognition highlights Medable’s dedication to patient-centric clinical trial solutions, exemplified by its Patient Caregiver Network (PCN). This network, a pioneering effort in the industry, comprises nearly 100 patient advocates and caregivers globally, representing diverse health conditions.
Medable’s PCN ensures the company’s solutions reflect diverse patient experiences. This focus on patient engagement is central to Medable’s platform development and has significantly shaped its clinical trial solutions. The company’s strategic partnership with Rare Patient Voice further expands its reach, incorporating feedback from over 1,600 patients participating in decentralized or hybrid trials.
Everest Group acknowledges Medable’s exceptional ability to integrate patient perspectives into clinical trials. The company’s innovative approaches have improved patient participation and adherence, setting a new standard for the industry. This patient-centric approach has also brought tangible benefits for patients and the clinical trial process.
Medable’s impact is evident in its widespread adoption and impressive results. The company’s software-as-a-service platform has been implemented in numerous decentralized and hybrid clinical trials across the globe, benefiting over a million patients and research participants. Customers using Medable’s platform have reported significant improvements, including faster enrollment rates and substantial cost reductions. A Tufts CSDD study underscores the financial advantages of decentralized trials, demonstrating significant potential return on investment, especially for Phase II and Phase III trials.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
